Orforglipron vs Wegovy Tablets

Both medicines work through the GLP-1 pathway, which helps reduce appetite, increase fullness, and support weight loss. In simple terms, both are designed to help you feel less hungry and eat less.  

The difference is in how the medicines are built and how they are taken. 

Orforglipron

Orforglipron is different because it is a small-molecule oral GLP-1 medicine, which is one reason it can be taken more flexibly. 

Wegovy tablets

Wegovy tablets contain semaglutide, which is a GLP-1 medicine already well known from injectable Wegovy and Ozempic.  

Orforglipron

Orforglipron activates the GLP-1 receptor. This helps reduce appetite, slows stomach emptying, and can help people feel fuller sooner and for longer.

Further reading: How does orforglipron work?

Wegovy tablets

Wegovy tablets also activate the GLP-1 receptor, so the end result is broadly similar: lower appetite, improved fullness, and reduced calorie intake.  

Which has the better mechanism?

From a patient point of view, neither has a clearly “better” mechanism. They work in similar ways. The bigger difference is practical use, not the basic appetite pathway.  

Orforglipron

Orforglipron is started at 0.8mg once daily for 30 days, then increased to 2.5mg, then 5.5mg. If needed and tolerated, it can then be increased further to 9mg, 14.5mg, or 17.2mg once daily.  

Further reading: Orforglipron dosage guide

Wegovy tablets

 Wegovy tablets start at 1.5mg once daily for 30 days, then increase to 4mg, then 9mg, then 25mg once daily as the recommended maintenance dose.  

Further reading: Wegovy tablets dosage guide

Dosage table 

This is one of the biggest differences. 

Orforglipron

Orforglipron can be taken once daily with or without food. The tablets should be swallowed whole, and you should not take more than one tablet per day.  

Wegovy tablets

Wegovy tablets need to be taken on an empty stomach, with no more than 4 ounces of plain water, and you must then wait at least 30 minutes before eating, drinking, or taking other oral medicines.  

Which is easier to take?

Orforglipron is clearly easier to take. It has fewer restrictions and should be easier for many people to fit into normal life.  

Orforglipron

In the orforglipron obesity study in adults without diabetes, average weight loss at 72 weeks was 7.4% with 5.5mg, 8.3% with 9mg, and 11.1% with 17.2mg, compared with 2.1% on placebo.  

Wegovy tablets

In the FDA label study for Wegovy tablets, adults without diabetes lost an average of 13.6% of body weight at 64 weeks, compared with 2.4% on placebo. 

Results table

Which gets better results?

Based on the current published figures, Wegovy tablets appear to deliver greater average weight loss.  

However, these were different trials, so this is not a direct head-to-head comparison. 

Both medicines have the familiar GLP-1 side-effect profile, especially: 

• nausea  
• diarrhoea  
• constipation  
• vomiting  
• abdominal discomfort  
• indigestion or reflux  
• reduced appetite  

Orforglipron

The Foundayo prescribing information lists nausea, diarrhoea, constipation, vomiting, dyspepsia, reflux, and abdominal pain among the common side effects. It also reports that 8% of patients in pooled placebo-controlled obesity trials discontinued treatment because of adverse reactions.  

Further reading: Side effects of orforglipron

Wegovy tablets

Wegovy tablets share the same broad GI side-effect pattern seen with semaglutide-based medicines. The FDA label includes warnings and adverse reactions consistent with the GLP-1 class.  

Further reading: Side effects of Wegovy tablets

Serious risks

For both medicines, important warnings include pancreatitis, gallbladder problems, kidney injury related to dehydration, and thyroid C-cell tumour warnings. They are generally avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2.  

Which has fewer side effects?

There is no clean direct answer yet. Both have similar class side effects, and tolerability will vary from person to person.  

Orforglipron

Lilly’s listed U.S. self-pay pricing is: 

• $149 for 0.8mg  
• $199 for 2.5mg  
• $299 for 5.5mg and 9mg  
• $349 for 14.5mg and 17.2mg  

Further reading: Where to buy orforglipron

Wegovy tablets

Novo Nordisk’s published U.S. self-pay pricing says: 

• $149 per month for 1.5mg and 4mg  
• $299 per month for 9 mg and 25mg  

Further reading: Where to buy Wegovy tablets

Which is cheaper? 

The pricing appears to be relatively similar in the U.S.  

UK pricing is yet to be confirmed.  

United States

Both products are now available in the U.S. Foundayo (orforglipron) received FDA approval in April 2026, and oral Wegovy tablets received FDA-approval in December 2025.  

United Kingdom

With both orforglipron and Wegovy tablets now licensed in the USA, there is growing expectation that the UK could follow within the next few months. However, no official date has been released by the MHRA, so any timeline for UK approval remains speculative at this stage. 

Orforglipron may be better if: 

• you want a tablet that is simpler to take  
• you do not want fasting instructions  
• you think you will be more consistent with a more flexible medicine  

Wegovy tablets may be better if: 

• your main priority is stronger published weight-loss results  
• you are happy following the empty-stomach routine  
• you are choosing primarily on efficacy rather than convenience